ASLN - ASLAN Pharmaceuticals Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.2100
+0.0500 (+1.58%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous close3.1600
Open3.1658
Bid2.71 x 1000
Ask6.00 x 1000
Day's range3.1400 - 3.2500
52-week range2.5100 - 10.4390
Volume13,729
Avg. volume25,060
Market cap107.307M
Beta (3Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
Trade prices are not sourced from all markets
  • The Wall Street Journallast month

    [$$] Aslan Reports Positive Data From Study Combining Its Drug With Chemotherapy

    Ltd. (ASLN) reported positive data Monday from a Phase 1b/2 trial of its varlitinib drug in combination with chemotherapy in first-line biliary tract cancer. The company said the responses in the trial were “impressive,” and that the drug has been well tolerated in biliary tract cancer patients. On Sunday, Aslan said a phase 2 combining varlitinib with mFOLFOX6 in gastric cancer patients didn’t meet its primary endpoint.

  • ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study
    Zackslast month

    ASLAN's Varlitinib Fails to Meet Endpoint in Phase II Study

    ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.

  • We're sorry, but this is all we were able to find on this topic.